Immunogenicity and safety of a new quadrivalent HPV vaccine in … – IARC

14 November 2023

A new study by researchers from the International Agency for Research on Cancer (IARC) shows that a new quadrivalent human papillomavirus (HPV) vaccine, which targets HPV types 6, 11, 16, and 18, is safe and effective in provoking an immune response against these HPV types. The study was published in the journal Lancet Oncology.

The researchers compared the efficacy and safety of the new quadrivalent HPV vaccine, given in two doses to girls and boys aged 914 years, with those of a comparable vaccine, given in three doses to women aged 1526 years. The results showed that the new quadrivalent HPV vaccine was as effective and as safe for the younger population as the comparable vaccine.

Access to this new, effective vaccine could help meet the global demand for HPV vaccines and boost coverage for both girls and boys globally.

Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 914 years versus an established quadrivalent HPV vaccine in women aged 1526 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial Lancet Oncol, Published online 7 November 2023; https://doi.org/10.1016/S1470-2045(23)00480-1

Read the article

Launch of online learning resources on cervical cancer screening

To mark three years of the global movement to eliminate cervical cancer, the International Agency...

17.11.2023

IARC-led study finds that 2 million lives are lost to preventable cancers each year across seven countries

Each year 1.9 million lives are lost to cancers caused by four preventable risk factors across th...

16.11.2023

Ultra-processed foods are associated with increased risk of cancer and cardiometabolic multimorbidity

In a ground-breaking multinational study, researchers from the International Agency for Research ...

14.11.2023

View original post here:

Immunogenicity and safety of a new quadrivalent HPV vaccine in ... - IARC

Related Posts
Tags: